Clinical Trial Update: Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression [Phase 1]

View source ↗

Summary

Phase 1 study of ADCT-502 in HER2-expressing advanced solid tumors including breast cancer and non-small cell lung cancer has terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Breast Cancer
• Gastroesophageal Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• ADCT-502 (disitamab vedotin)

Snippet

Sponsor: ADC Therapeutics S.A. | Conditions: Breast Cancer, Non Small Cell Lung Cancer | Phase 1 | Status: TERMINATED | Results posted: 2019-08-28